Patents Examined by Fiona T. Powers
  • Patent number: 8288393
    Abstract: The present invention relates to a nitrogen-containing heterocyclic compound or salt thereof, represented by the following formula (I), and a pest control agent containing the compound or salt thereof, as an active ingredient of the pest control agent: (wherein, R0 represents a halogen atom, or the like; Z represents an unsubstituted or substituted aryl group, or the like; Y represents a nitro group, or the like; n represents an integer of 0 to 3; D represents a 5-membered to 8-membered hydrocarbon ring group or heterocyclic group; X represents a functional group represented by the following formula (II)-1 or formula (II)-2: (wherein, in the formula (II)-1, the dotted line represents a single bond or double bond, and R1 and R2 respectively and independently represent a hydrogen atom, nitro group, hydroxyl group, mercapto group, unsubstituted or substituted amino group, or organic group; and, in the formula (II-2), W represents an oxygen atom or sulfur atom; and, R11 represents a hydrogen atom, hydrox
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: October 16, 2012
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Jyun Iwata, Masahiro Kawaguchi
  • Patent number: 8283491
    Abstract: The present invention is directed to an isomerized alpha olefin sulfonate and a method of making the same wherein the isomerized alpha olefin sulfonate is derived from sulfonating an isomerized alpha olefin with sulfur trioxide in the presence of air thereby producing an isomerized alpha olefin sulfonic acid, wherein the isomerized alpha olefin is derived from the isomerization of C12-C40 normal alpha olefins; and neutralizing the isomerized alpha olefin sulfonic acid with a source of a mono-valent cation.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: October 9, 2012
    Assignee: Chevron Oronite Company LLC
    Inventors: Curtis Bay Campbell, Theresa Ann Denslow
  • Patent number: 8283453
    Abstract: The present invention provides a method for selectively placing carbon nanotubes on a substrate surface by using functionalized carbon nanotubes having an organic compound that is covalently bonded to such carbon nanotubes. The organic compound comprises at least two functional groups, the first of which is capable of forming covalent bonds with carbon nanotubes, and the second of which is capable of selectively bonding metal oxides. Such functionalized carbon nanotubes are contacted with a substrate surface that has at least one portion containing a metal oxide. The second functional group of the organic compound selectively bonds to the metal oxide, so as to selectively place the functionalized carbon nanotubes on the at least one portion of the substrate surface that comprises the metal oxide.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: October 9, 2012
    Assignee: International Business Machines Corporation
    Inventors: Ali Afzali-Ardakani, Phaedon Avouris, James B. Hannon, Christian Klinke
  • Patent number: 8273877
    Abstract: Substituted tetraazapentalenes have two benzenoid rings and eight substitutable positions. Substitutions are made of hydrogen or C—H groups in favor of amino groups, nitro groups or nitrogen atoms. The tetraazapentalenes are synthesized through an intermediate azo, which is made from a 1:1:1 molar ratio of a nitroaniline, sodium nitrite and an amine.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: September 25, 2012
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Alfred G. Stern, Patrick A. Caruana
  • Patent number: 8269032
    Abstract: The present invention relates to isonitrile compounds, methods of synthesis, and uses in a variety of fields. In one aspect, the present invention includes sulfinyl methyl isonitriles and methods for their preparation. In another aspect, the present invention includes the use of sulfinyl methyl isonitriles to prepare various other isonitrile compounds and derivatives thereof. In yet another aspect, the present invention includes a relatively simple and routine synthesis of sulfinyl methyl isonitrile compounds, other isonitrile compounds and derivatives thereof.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: September 18, 2012
    Assignee: Duquesne University of the Holy Ghost
    Inventors: Fraser Ferguson Fleming, Bhaskar Reddy Pitta
  • Patent number: 8263579
    Abstract: This invention relates to novel compounds obtained by fermentation of Myxobacteria strain (PM0670013/MTCC 5570). The present invention further relates to the processes for the production of the novel anti-inflammatory compounds, to the culture no. PM0670013 (MTCC 5570), and to pharmaceutical compositions containing compounds of the present invention as an active ingredient and its use in medicines for the treatment of inflammatory diseases or disorders mediated by proinflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-?) and/or interleukins such as IL-6, having anti-inflammatory activity The invention also includes all stereoisomeric forms of compounds of the present invention.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: September 11, 2012
    Assignee: Piramal Healthcare Limited
    Inventors: Koteppa Pari, Girish Badrinath Mahajan, Nidhi Tomar, Vijaya Phani Kumar Yemparala, Asha Adrian Kulkarni-Almeida, Saji George
  • Patent number: 8258119
    Abstract: The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: September 4, 2012
    Assignee: Kasina Laila Innova Pharmaceuticals
    Inventors: Ganga Raju Gokaraju, Sudhakar Kasina, Rama Raju Gokaraju, Trimurtulu Golakoti, Venkateswarlu Somepalli, Sengupta Krishanu, Kiran Bhupathiraju
  • Patent number: 8242300
    Abstract: The present invention relates to selective partial oxidation of methane in the absence of a solvent such as sulfuric acid or oleum.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: August 14, 2012
    Assignee: Dow Global Technologies LLC
    Inventors: Michael A. Gonzalez, Daniel R. Henton, David C. Molzahn
  • Patent number: 8222274
    Abstract: [Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).
    Type: Grant
    Filed: February 19, 2007
    Date of Patent: July 17, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Ryushi Seo, Hidetaka Kaku, Hiroyoshi Yamada, Daisuke Kaga, Shinobu Akuzawa
  • Patent number: 8217022
    Abstract: The present invention refers to analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for the treatment of different types of tumors. Said compounds show cytotoxicity at very low concentrations (IC50 0.22 to 12.8 ?M), and good solubility. These compounds can be used in the treatment of tumor patients as single drugs or in combination with other cytostatics.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: July 10, 2012
    Assignee: Rudjer Boskovic Institute
    Inventors: Maja Osmak, Slovenko Polanc, Tamara Cimbora Zovko, Anamaria Brozovic, Marijan Kocevar, Vita Majce, Branko Alic
  • Patent number: 8217021
    Abstract: New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: July 10, 2012
    Assignee: Pliva Hrvatska D.O.O.
    Inventors: Edislav Leksic, Helena Ceric, Tina Mundorfer, Irena Zrinski Antonac, Zrinka Mastelic Samardzic
  • Patent number: 8183375
    Abstract: The present invention describes novel dyes, including coumarins, rhodamines, and rhodols that incorporate additional fused aromatic rings. The dyes of the invention absorb at a longer wavelength than structurally similar dyes that do not possess the fused aromatic rings. Many of the dyes of the invention are useful fluorescent dyes. The invention includes chemically reactive dyes, dye-conjugates, and the use of such dyes in staining samples and detecting ligands or other analytes.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: May 22, 2012
    Assignee: Life Technologies Corporation
    Inventors: Zhenjun Diwu, Jixiang Liu, Kyle Gee
  • Patent number: 8173700
    Abstract: The present invention relates to salts of substituted allophanates, methods for their production, medicaments containing said compounds and the use of said compound for the production of medicaments.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: May 8, 2012
    Assignee: Gruenenthal GmbH
    Inventors: Robert Frank, Ruth Jostock, Hans Schick, Fritz Theil, Olga Groeger, Rene Kudick, Helmut Sonnenschein, Birgitta Henkel
  • Patent number: 8168764
    Abstract: Provided is a polyfunctional compound which can be used as an optical recording material in which a large quantity of information data can be recorded optically at a high density, which can be used as an optical waveguide material using a refractive index difference occurring between a light-irradiated part and a part not irradiated with light, and which is capable of forming a film and can be used as a photo-alignment film material having excellent photosensitivity.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: May 1, 2012
    Assignee: Nitto Denko Corporation
    Inventors: Sadahiro Nakanishi, Mitsuru Ueda
  • Patent number: 8163743
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: April 24, 2012
    Assignee: GlaxoGroupLimited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Katherine Louise Jones, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, Christian Alan Paul Smethurst, Yoshiaki Washio
  • Patent number: 8153655
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: April 10, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jesus Gonzalez, III, Andreas Termin, Esther Martinborough, Nicole Zimmermann
  • Patent number: 8148401
    Abstract: The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: April 3, 2012
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Lawrence A. Reiter, Susan D. La Greca, Christopher S. Jones, Qifang Li
  • Patent number: 8143382
    Abstract: The invention provides a specific pyrazole disazo dye which is a yellow dye having excellent solubility in nonpolar solvents, in particular, hydrocarbon solvents, and having a high extinction coefficient. The dye preferably is preferably a pyrazole disazo dye represented by the following general formula (I): (wherein R1 represents a C2-C10 alkyl group; R2 represents a C3-C10 alkyl group; the six-membered ring A represents a phenyl group which may have a substituent; and the six-membered ring B represents a phenylene group which may have a substituent).
    Type: Grant
    Filed: November 11, 2008
    Date of Patent: March 27, 2012
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Yasushi Shiga, Mio Ishida
  • Patent number: 8143237
    Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: March 27, 2012
    Assignee: Kasina Laila Innova Pharmaceuticals Private Limited
    Inventors: Ganga Raju Gokaraju, Sudhakar Kasina, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Venkateswarlu Somepalli, Trimurtulu Golakoti, Kiran Bhupathiraju, Sengupta Krishanu, Venkata Krishna Raju Alluri
  • Patent number: 8138182
    Abstract: The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: March 20, 2012
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Akira Hatayama, Hiroshi Tsuruta, Yasuo Ochi, Haruo Imawaka, Kazuyuki Ohmoto